Non-muscle-invasive bladder cancer
Most bladder cancers are found while still confined to the lining. They are scraped out through the urethra and, when higher risk, treated with BCG instilled into the bladder; the challenge is the frequent recurrences and the patients whose tumours stop responding to BCG.
Overview
Non-muscle-invasive bladder cancer includes papillary tumours confined to the mucosa (Ta) or lamina propria (T1) and flat carcinoma in situ. It is diagnosed by cystoscopy and removed by transurethral resection, with a single immediate dose of intravesical chemotherapy for low-risk tumours. Intermediate- and high-risk disease receives induction and maintenance intravesical BCG, the oldest cancer immunotherapy in use, which halves recurrence and reduces progression. Tumours that recur despite adequate BCG are called BCG-unresponsive; radical cystectomy is the standard, and bladder-sparing alternatives have arrived: pembrolizumab (KEYNOTE-057), nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, the gemcitabine-releasing device TAR-200 and the oncolytic virus cretostimogene. Worldwide BCG shortages have pushed dose-reduction and chemotherapy substitutes into practice. Blue-light cystoscopy improves detection of flat lesions.
State of the art
- BCG remains the standard forty years on, and shortages have shown how much depends on one biologic.
- Four bladder-sparing options for BCG-unresponsive disease have been approved or reached late trials since 2020, an unprecedented pace for this stage.
- Intravesical drug-releasing devices and gene therapies show that local delivery, not systemic drugs, is the frontier here.
Anatomy and lymph node drainage
Renal cell carcinoma comes from the kidney's filtering cortex, urothelial cancer from the lining of the collecting system and bladder, and the adrenal on top hosts cortical and medullary (neuroblastoma) tumours.
- Renal cortex (RCC)Low-grade Ta papillary tumours (low risk)
- Renal pelvis and ureter (upper tract urothelial)Upper tract urothelial carcinoma of the renal pelvis and ureter (related)
- Bladder lining (non-muscle-invasive)Low-grade Ta papillary tumours (low risk) · High-grade Ta and T1 tumours (high risk) · Upper tract urothelial carcinoma of the renal pelvis and ureter (related)
- Bladder muscle wall (muscle-invasive)
- Adrenal cortex
- Adrenal medulla and sympathetic chain (neuroblastoma)
- Developing kidney (Wilms tumour)
- renal hilar
- para-aortic and paracaval
- obturator and iliac (bladder)
Same organ: Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Clear cell renal cell carcinoma, Papillary renal cell carcinoma, Chromophobe renal cell carcinoma, Renal cell carcinoma, Wilms tumour (nephroblastoma), Neuroblastoma (paediatric), Adrenocortical carcinoma, Pheochromocytoma and paraganglioma (PPGL), Urethral cancer, Penile cancer
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- About three quarters of new bladder cancers; rarely fatal at this stage but it recurs in half of patients and progresses to muscle invasion in a fifth of the high-risk group, so years of cystoscopic surveillance make it one of the most expensive cancers to manage.
- AI in radiologyEstablished
- cfDNA fragmentomicsEstablished
- Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)Standard of care
- DNA methylation profilingEstablished
- HCC surveillance in cirrhosis (ultrasound + AFP)Standard of care
- High-risk pancreatic surveillance (CAPS / PRECEDE)Established
- A 28-day national pathway for people with a positive multi-cancer blood test
- A breath test to rule out cancer in people with vague symptoms
- A cancer blood test for older people arriving at A&E with unexplained symptoms
- A legislated, publicly reported 28-day standard from urgent referral to diagnosis
- A live national dashboard of stage at diagnosis as the scorecard for early detection
- A single 'cancer check at 60' appointment bundling all screening tests
Background: Alpha-fetoprotein (AFP), Barrett's oesophagus, CA 19-9, Early detection, Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Cystoscopy, transurethral resection with muscle in the specimen, blue-light or enhanced imaging for carcinoma in situ; re-resection of T1 tumours.
Single immediate instillation of mitomycin or gemcitabine after resection; surveillance cystoscopy.
Induction and one to three years of maintenance BCG; intravesical chemotherapy when BCG is unavailable; early cystectomy for the highest-risk T1 disease.
Radical cystectomy, or bladder-sparing treatment: pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, TAR-200, cretostimogene in trials and early approvals.
Subtypes & biomarkers
top- Low-grade Ta papillary tumours (low risk)
- High-grade Ta and T1 tumours (high risk)
- Carcinoma in situ
- BCG-unresponsive disease
- Upper tract urothelial carcinoma of the renal pelvis and ureter (related)
- Grade and stage (EAU and AUA risk groups)
- Carcinoma in situ and lymphovascular invasion
- FGFR3 mutations (common in low-grade disease)
- Urinary biomarkers and cytology for surveillance
- Molecular subtypes under study
How often this target appears
- 1976Morales reports intravesical BCG
- 1990BCG approved for carcinoma in situ of the bladder
- 2020Pembrolizumab approved for BCG-unresponsive carcinoma in situ
- 2022Nadofaragene firadenovec: first gene therapy for bladder cancer
- 2024Nogapendekin alfa inbakicept with BCG approved
What is in development for Non-muscle-invasive bladder cancer, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Drugs in phase 3 · 1
Open problems and what is being done
Recurrent BCG shortages.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- Mitomycin CApproved
- Liquid biopsy (ctDNA)Standard of care
- MRD / molecular residual disease testingEstablished
- Multiparameter flow cytometry MRDStandard of care
- NGS-based MRD (clonoSEQ and molecular MRD)Standard of care
- SignateraEstablished
In trials- ADAURAPositive
- CAMBRIA-1 & CAMBRIA-2Active
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)Emerging
- DYNAMICPositive
- IMvigor011Positive
Ideas and roadmaps- A blood test for the pre-metastatic niche
- A bone marrow niche on a chip to study human dormancy
- A dedicated clinic for people whose blood test says the cancer is back
- A drug screen that only rewards killing sleeping cancer cells
- A national platform trial that every ctDNA-positive patient can join
- A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Background: Circulating tumour DNA (ctDNA), Disseminated tumour cells (DTCs), Late recurrence, Minimal / molecular residual disease (MRD), MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶). Also on OnCo: Treatment journeys · Survivorship planner.
Predicting who will progress to muscle invasion.
The burden and cost of lifelong cystoscopy.
and how the field plans to fix it →What is being done about thisCost and accessAvailable now- HPV & HBV vaccinationStandard of care
- ImatinibApproved
- Trastuzumab biosimilarsApproved
In trials- Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)Positive
- IARC India HPV vaccine dose study (one, two or three doses)Positive
- IMAGINE (varnimcabtagene autoleucel, Immuneel)Positive
- Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Positive
- Low-dose olanzapine for cancer anorexia (Tata Memorial)Positive
- METRO PLUS (Tata Memorial Centre, Varanasi)Positive
Ideas and roadmaps- 90-day reliance approval for cancer drugs cleared by two stringent regulators
- A cheap old tablet to restore appetite
- A combination pricing rule so two-drug regimens are not priced as two monopolies
- A coordinated reserve and shared schedule for the world's medical isotope reactors
- A dedicated global financing window for cancer, modelled on the Global Fund
- A delinked market-entry reward paid by payers when a repurposed generic wins approval
Background: Accelerated approval, Biosimilar, Real-world evidence. Also on OnCo: Financial help · Coverage by country · HTA decisions.
Comparing the new bladder-sparing options with each other and with cystectomy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Expert centres
topExpert centres
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
- Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer CenterBaltimore, USNewsweek oncology #10NCI comprehensivevia Pembrolizumab
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
- Alliance for Clinical Trials in OncologyChicago, IL, USvia Pembrolizumab
- ANZUP Cancer Trials GroupSydney, AUvia Bladder & urothelial cancer
- Cedars-Sinai CancerLos Angeles, CA, USvia Bladder & urothelial cancer
- GOG FoundationPhiladelphia, PA, USvia Pembrolizumab
- via Bladder & urothelial cancer
- Institut Jules BordetBrussels, BEvia Pembrolizumab
- via Bladder & urothelial cancer
- via Pembrolizumab
- via Gemcitabine
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
- via Bladder & urothelial cancer
Questions to ask
topQuestions to ask your oncologist about Non-muscle-invasive bladder cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Grade and stage, Carcinoma in situ and lymphovascular invasion, FGFR3 mutations, Urinary biomarkers and cytology for surveillance, Molecular subtypes under study), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Low-grade Ta papillary tumours, High-grade Ta and T1 tumours, Carcinoma in situ.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Diagnosis and resection
- For my situation (diagnosis and resection), which of the standard options do you recommend and why?Why: Guideline options include: Cystoscopy, transurethral resection with muscle in the specimen, blue-light or enhanced imaging for carcinoma in situ; re-resection of T1 tumours.
Low risk
- For my situation (low risk), which of the standard options do you recommend and why?Why: Guideline options include: Single immediate instillation of mitomycin or gemcitabine after resection; surveillance cystoscopy.
- Am I a candidate for Mitomycin C, Gemcitabine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Intermediate and high risk
- For my situation (intermediate and high risk), which of the standard options do you recommend and why?Why: Guideline options include: Induction and one to three years of maintenance BCG; intravesical chemotherapy when BCG is unavailable; early cystectomy for the highest-risk T1 disease.
BCG-unresponsive
- For my situation (bcg-unresponsive), which of the standard options do you recommend and why?Why: Guideline options include: Radical cystectomy, or bladder-sparing treatment: pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, TAR-200, cretostimogene in trials and early approvals.
- Am I a candidate for Pembrolizumab, Nadofaragene firadenovec, Nogapendekin alfa inbakicept or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Gemcitabine intravesical system (TAR-200), Cretostimogene grenadenorepvec?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “Recurrent BCG shortages”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Predicting who will progress to muscle invasion”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
7targets
1drugs
7companies
6terms
1Latest papers
topQuery for this cancer: (TITLE:"Non-muscle-invasive bladder cancer" OR ABSTRACT:"Non-muscle-invasive bladder cancer" OR TITLE:"NMIBC" OR ABSTRACT:"NMIBC" OR TITLE:"Superficial bladder cancer" OR ABSTRACT:"Superficial bladder cancer" OR TITLE:"Ta, T1 and carcinoma in situ of the bladder" OR ABSTRACT:"Ta, T1 and carcinoma in situ of the bladder") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Non-muscle-invasive bladder cancer, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerMuscle-invasive and advanced bladder cancer
Shares Radical cystectomy, Gemcitabine, Bladder & urothelial cancer, Pembrolizumab and the tag subtype-page.
- CancerClear cell ovarian cancer
Shares Pembrolizumab and the tag subtype-page.
- CancerLeiomyosarcoma
Shares Gemcitabine and the tag subtype-page.
- CancerPapillary renal cell carcinoma
Shares Pembrolizumab and the tag subtype-page.
- CancerPeritoneal mesothelioma
Shares Pembrolizumab and the tag subtype-page.
- CancerOral cavity cancer (mouth and tongue)
Shares Pembrolizumab and the tag subtype-page.
- CancerAnaplastic thyroid cancer
Shares Pembrolizumab and the tag subtype-page.
- CancerLaryngeal and hypopharyngeal cancer
Shares Pembrolizumab and the tag subtype-page.